These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22724482)

  • 1. Diabetes as a negative risk factor for abdominal aortic aneurysm - does the disease aetiology or the treatment provide the mechanism of protection?
    Torsney E; Pirianov G; Cockerill GW
    Curr Vasc Pharmacol; 2013 May; 11(3):293-8. PubMed ID: 22724482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of thiazolidinediones beyond glycaemic control.
    Kalaitzidis RG; Sarafidis PA; Bakris GL
    Curr Pharm Des; 2009; 15(5):529-36. PubMed ID: 19199979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.
    Diamant M; Heine RJ
    Drugs; 2003; 63(13):1373-405. PubMed ID: 12825962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone reduces the development and rupture of experimental aortic aneurysms.
    Jones A; Deb R; Torsney E; Howe F; Dunkley M; Gnaneswaran Y; Gaze D; Nasr H; Loftus IM; Thompson MM; Cockerill GW
    Circulation; 2009 Jun; 119(24):3125-32. PubMed ID: 19506106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?
    Doggrell SA
    Expert Opin Pharmacother; 2008 Feb; 9(3):405-20. PubMed ID: 18220491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
    Simó R; Rodriguez A; Caveda E
    Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes mellitus as a protective factor of abdominal aortic aneurysm: Possible mechanisms.
    Climent E; Benaiges D; Chillarón JJ; Flores-Le Roux JA; Pedro-Botet J
    Clin Investig Arterioscler; 2018; 30(4):181-187. PubMed ID: 29580664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
    Chiquette E; Ramirez G; Defronzo R
    Arch Intern Med; 2004 Oct; 164(19):2097-104. PubMed ID: 15505122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
    Haberbosch W
    Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
    Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
    Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone Identifies a New Target for Aneurysm Treatment: Role of Egr1 in an Experimental Murine Model of Aortic Aneurysm.
    Charolidi N; Pirianov G; Torsney E; Pearce S; Laing K; Nohturfft A; Cockerill GW
    J Vasc Res; 2015; 52(2):81-93. PubMed ID: 26113112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm.
    Golledge J; Cullen B; Rush C; Moran CS; Secomb E; Wood F; Daugherty A; Campbell JH; Norman PE
    Atherosclerosis; 2010 May; 210(1):51-6. PubMed ID: 19926086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels.
    Olansky L; Marchetti A; Lau H
    Clin Ther; 2003; 25 Suppl B():B64-80. PubMed ID: 14553867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes and aortic aneurysm: current state of the art.
    Raffort J; Lareyre F; Clément M; Hassen-Khodja R; Chinetti G; Mallat Z
    Cardiovasc Res; 2018 Nov; 114(13):1702-1713. PubMed ID: 30052821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes Mellitus: Is It Protective against Aneurysm? A Narrative Review.
    Patel K; Zafar MA; Ziganshin BA; Elefteriades JA
    Cardiology; 2018; 141(2):107-122. PubMed ID: 30453299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present.
    Yasmin S; Jayaprakash V
    Eur J Med Chem; 2017 Jan; 126():879-893. PubMed ID: 27988463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone and lipid metabolism.
    Ferrannini E
    Diabetologia; 2005 Jan; 48(1):6-7. PubMed ID: 15624094
    [No Abstract]   [Full Text] [Related]  

  • 20. Pleiotropic effects of thiazolidinediones.
    Rizos CV; Liberopoulos EN; Mikhailidis DP; Elisaf MS
    Expert Opin Pharmacother; 2008 May; 9(7):1087-108. PubMed ID: 18422468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.